Drug Discovery World

SEPTEMBER 6, 2022

Tony Khoury, Executive Vice President of Project Farma and Anshul Mangal , President & General Counsel of Project Farma, share how the industry is leveraging stronger education programmes to close the advanced therapy talent gap. . The need for solutions to the industry’s biggest bottlenecks are growing daily. .

Therapies 130

Therapies Clinical Trials Government Production 130

PLOS: DNA Science

MARCH 21, 2024

The Food and Drug Administration just announced approval of Lenmeldy (atidarsagene autotemcel), a gene therapy to treat the neurological condition metachromatic leukodystrophy (MLD). The history of gene therapy for MLD is compelling – DNA Science covered it for Rare Disease Day in 2021, here. She passed away in 2013.

Therapies 89

Therapies Clinical Trials DNA Trials 89

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. billion, compared to $19.9 Cancer is king .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

MARCH 1, 2024

Pepaxto associated with increased risk of death The FDA is alerting patients and health care professionals that a clinical trial (OCEAN, Study OP-103) evaluating Pepaxto with dexamethasone showed an increased risk of death. The FDA has now suspended enrolment in all ongoing Pepaxto clinical trials.

FDA 130

FDA Clinical Trials FDA Approval Trials 130

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. Hearing aids also have all sorts of deficits.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

KIF1A

APRIL 25, 2024

She is scheduled to be the 2nd patient in the world to receive ASO therapy for KAND. Timeline: December 2021 – We met with Dr Chung in NYC and discussed and applied to n-Lorem. March 2023 – We met with n-Lorem and found out Susannah’s ASO (1st KAND patient to receive ASO therapy for KAND) would work for Sloane.

Therapies 52

Therapies FDA Approval FDA Hospitals 52

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. “We In 2021 there were an estimated 1.5

Research 130

Research Clinical Trials Therapies Clinical Development 130

The Pharma Data

AUGUST 5, 2020

Company expect to file regulatory submissions in 2021. Novartis has revealed positive results from a phase 2 study of its CAR-T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma. Source link.

Therapies 52

Therapies Trials Treatment FDA 52

Drug Discovery World

FEBRUARY 10, 2023

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, despite a drop in activity, according to analysis from analytics company Phesi. However, the reduction in breast cancer trials is unexpected, with 113 fewer recruiting trials in 2022 compared with 2021.

Disease 130

Disease Clinical Trials Clinical Development Trials 130

Drug Discovery World

JULY 20, 2022

In 2021, the first KRAS-inhibitor was approved for use in non-small-cell lung cancer cases with the KRAS? Whilst there are ongoing trials assessing its effectiveness alongside immunotherapy, most trials only involve patients who have already been through immune checkpoint blockade and have not responded. mutation. .

Therapies 130

Therapies Clinical Trials Treatment Trials 130

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Therapies 119

Therapies FDA FDA Approval Treatment 119

Drug Discovery World

SEPTEMBER 17, 2024

I am the lead scientist on our oncology and infectious disease programmes, where I manage and oversee everything related to drug discovery and work closely with our VP of Clinical Operations on our clinical trials. The highlight of my career has undoubtedly been taking on the role of Principal Scientist at Poolbeg Pharma.

Research 221

Research Clinical Trials Disease Trials 221

Advarra

JUNE 20, 2023

Additionally, in 2021, a literature review estimated the average capitalized research and development (R&D) costs per new cancer medicine at between $944 million and $4.54 Innovation Organizations conducting oncology clinical trials face challenges distinct from the rest of the research community.

Trials 52

Trials Clinical Trials FDA Approval Animal Testing 52

Drug Discovery World

MAY 8, 2024

The ORCA-V1 trial was led by Achieve Life Sciences, and co-led by an investigator from Massachusetts General Hospital. In their previous clinical trial, the research team found that cytisinicline helped people to quit smoking traditional cigarettes. among all adults in the US and 11% among adults aged 18-24 used e-cigarettes in 2021.

Clinical Trials 182

Clinical Trials Compliance Trials Drugs 182

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Therapies 52

Therapies FDA Clinical Trials Production 52

The Pharma Data

MAY 17, 2021

Sponsors using master protocols to test new drugs and therapies for treating or preventing COVID-19 should base their analyses on comparisons between control arm participants who were concurrently randomized, the FDA advised in a final guidance released yesterday. Read the guidance here: www.fdanews.com/05-17-21-COVID-19.pdf.

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We Second Quarter 2021 Financial Results. Total second quarter 2021 revenue of $6.2 As of June 30, 2021, Gilead had $7.4

Science 52

Science Production Treatment FDA 52

Drug Discovery World

DECEMBER 13, 2022

An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. . The trial results have been revealed by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. . Clinical trial details .

Clinical Trials 130

Clinical Trials Trials Therapies Clinical Research 130

The Pharma Data

JANUARY 11, 2021

Pfizer has started dosing in a phase 3 study evaluating its investigational gene therapy, PF-06939926, in young male patients with Duchenne muscular dystrophy (DMD). The trial plans to enroll 99 boys aged 4 to 7 years across 55 sites in 15 countries. PF-06939926 received Fast-Track designation from the FDA in October. Source link.

Therapies 52

Therapies FDA Trials Treatment 52

The Pharma Data

JANUARY 27, 2021

Pfizer’s and Myovant Sciences’ investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1 mg and norethindrone acetate 0.5 mg) helped reduce menstrual pain and nonmenstrual pelvic pain in women with endometriosis, according to findings from a phase 3 trial. Data from the study found that 84.8

Science 52

Science Therapies Treatment Trials 52

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research Government 52

Chemical Biology and Drug Design

OCTOBER 10, 2023

million people worldwide were living with HIV in 2021. Several agents are in clinical trials, including apricitabine, racivir, elvucitabine, doravirine, dapivirine, and elsulfavirine. Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide.

FDA Approval 100

FDA Approval Clinical Trials FDA Virus 100

The Pharma Data

MARCH 11, 2021

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. LY3484356, an oral SERD, is currently being studied in a Phase 1/2 clinical trial.

Research 52

Research Clinical Trials FDA Approval Trials 52

Drug Discovery World

NOVEMBER 17, 2022

It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW. However, finding suitable patients willing to take part in research and trials of new drugs is difficult, which impacts the discovery process. DDW speaks to him about VAXO-Q-RE developments, a combination immunotherapy that will soon enter clinical trials.

Clinical Trials 130

Clinical Trials Trials Therapies Research 130

Drug Discovery World

NOVEMBER 17, 2022

It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW. However, finding suitable patients willing to take part in research and trials of new drugs is difficult, which impacts the discovery process. DDW speaks to him about VAXO-Q-RE developments, a combination immunotherapy that will soon enter clinical trials.

Clinical Trials 130

Clinical Trials Trials Therapies Production 130

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. Patients and caregivers also assess the benefits offered by different therapies, weighing the progression-free survival with their off-target effects. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Discovery World

JULY 11, 2023

There is a significant unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases. The partnership has already been successful in generating a pipeline of discovery and pre-clinical-stage programmes.

Licensing 189

Licensing Licensing Drugs Disease 189

PLOS: DNA Science

OCTOBER 12, 2023

In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Discovery World

NOVEMBER 7, 2023

Work is underway at The University of Queensland’s (UQ) BASE facility which has become Australia’s leading provider of mRNA for research and pilot studies since its launch in 2021. “We aim to begin manufacturing mRNA for Phase I clinical trials in 2024.”

Clinical Trials 130

Clinical Trials Government Vaccine Laboratories 130

Drug Discovery World

OCTOBER 19, 2022

Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India, which has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. .

RNA 130

RNA DNA Clinical Trials Therapies 130

The Pharma Data

APRIL 7, 2021

today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. . Key AbbVie abstracts and presentation details for the 2021 AAN Annual Meeting program are outlined below. Clinical Trials Plenary Session.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

Drug Discovery World

NOVEMBER 14, 2023

Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. Alongside surgery, radiation and chemotherapy, antibody-based immunotherapy is considered to be a main component of cancer therapy 1. billion in 2021, and is projected to reach $106.8

Disease 147

Disease FDA Approval Treatment FDA 147

The Pharma Data

MAY 26, 2023

State-of-the-art cryogenic freezers alongside material transfer equipment have been installed that are designed to retain the integrity of investigational advanced therapy products by minimizing their time-out-of-environment. With sites in the U.S.,

Clinical Supply 52

Clinical Supply Therapies Clinical Trials Packaging 52

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. During the period 2016-2021, the Brazilian, Chinese and Indian markets grew by 11.7%, 6.7% The CDD will sponsor and manage KWF-supported trials.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

The Pharma Data

MARCH 20, 2021

Precision imaging analytics technology known as radiomics will see increased adoption in 2021 and will be incorporated into drug development strategies and clinical trials management, according to Rose Higgins, CEO of HealthMyne.

Clinical Trials 52

Clinical Trials Drug Development Trials Drugs 52